Inositol’s and other nutraceuticals’ synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives

References

• Genazzani AD, Prati A, Santagni S, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol 2012;28:969–73
   PubMed Web of Science ®Google Scholar
• Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:99–109
   PubMed Web of Science ®Google Scholar
• Sir-Petermann T, Angel B, Maliqueo M, et al. Prevalence of type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia 2002;45:959–64
   PubMed Web of Science ®Google Scholar
• Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006;119:S10–6
   PubMed Web of Science ®Google Scholar
• Erol A. Insulin resistance is an evolutionarily conserved physiological mechanism at the cellular level for protection against increased oxidative stress. Bioessays 2007;29:811–18
   PubMed Web of Science ®Google Scholar
• Watve MG, Yajnik CS. Evolutionary origins of insulin resistance: a behavioral switch hypothesis. BMC Evol Biol 2007;7:61
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–607
   PubMed Web of Science ®Google Scholar
• Paul C, Brady DM. Inositol modulation of essential metabolic pathways of insulin resistance in metabolic syndrome, polycystic ovarian syndrome, and type 2 diabetes. Townsend Lett 2015;August/Sep:101–8
   Google Scholar
• Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem 2005;51:931–8
   PubMed Web of Science ®Google Scholar
• Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006;83:1237–47
   PubMed Web of Science ®Google Scholar
• Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012;148:852–71
   PubMed Web of Science ®Google Scholar
• Ye J. Mechanisms of insulin resistance in obesity. Front Med 2013;7:14–24
   PubMed Web of Science ®Google Scholar
• Parikh R, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocrinol Metab 2012;16:7–12
   PubMedGoogle Scholar
• Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 2003;7:151–9
   PubMedGoogle Scholar
• Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature 2006;443:651–7
   PubMed Web of Science ®Google Scholar
• Isabella R, Raffone E. Does ovary need d-chiro-inositol? J Ovarian Res 2012;5:14
   PubMed Web of Science ®Google Scholar
• Larner J. D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002;3:47–60
   PubMedGoogle Scholar
• Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 2013;95:1811–27
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, et al. Altered d-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29:300–5
   PubMed Web of Science ®Google Scholar
• Kawa JM, Przybylski R, Taylor CG. Urinary chiro-inositol and myo-inositol excretion is elevated in the diabetic db/db mouse and streptozotocin diabetic rat. Exp Biol Med (Maywood) 2003;228:907–14
   PubMed Web of Science ®Google Scholar
• Campbell WW, Ostlund RE, Joseph LJ, et al. Relationships of plasma C-peptide and gender to the urinary excretion of inositols in older people. Horm Metab Res 2001;33:44–51
   PubMed Web of Science ®Google Scholar
• Unfer V, Porcaro G. Updates on the myo-inositol plus d-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol 2014;7:623–31
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139–44
   PubMed Web of Science ®Google Scholar
• Artini PG, Di Berardino OM, Papini F, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 2013;29:375–9
   PubMed Web of Science ®Google Scholar
• Venturella R, Mocciaro R, De Trana E, et al. Assessment of the modification of the clinical, endocrinal and metabolical profile of patients with PCOS syndrome treated with myo-inositol. Minerva Ginecol 2012;64:239–43
   PubMedGoogle Scholar
• Papaleo E, Unfer V, Baillargeon J-P, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007;23:700–3
   PubMed Web of Science ®Google Scholar
• Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012;28:509–15
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V, Baillargeon JP, et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91:1750–4
   PubMed Web of Science ®Google Scholar
• Chiu TTY, Rogers MS, Law ELK, et al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002;17:1591–6
   PubMed Web of Science ®Google Scholar
• Unfer V, Carlomagno G, Rizzo P, et al. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci 2011;15:452–7
   PubMed Web of Science ®Google Scholar
• Ciotta L, Stracquadanio M, Pagano I, et al. Effects of inositol on oocyte quality in patients affected with polycystic ovary syndrome. Minerva Ginecol 2010;62:525–31
   PubMedGoogle Scholar
• D'Anna R, Scilipoti A, Giordano D, et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care 2013;36:854–7
   PubMed Web of Science ®Google Scholar
• Matarrelli B, Vitacolonna E, D’Angelo M, et al. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med 2013;26:967–72
   PubMed Web of Science ®Google Scholar
• D’Anna R, Di Benedetto V, Rizzo P, et al. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol 2012;28:440–2
   PubMed Web of Science ®Google Scholar
• Noventa M, Vitagliano A, Quaranta M, et al. Preventive and therapeutic role of dietary inositol supplementation in periconceptional period and during pregnancy: a summary of evidences and future applications. Reprod Sci 2015;pii:1933719115594018 [Epub ahead of print]
   Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
   Web of Science ®Google Scholar
• Vitagliano A, Quaranta M, Noventa M, Gizzo S. “Empiric” inositol supplementation in normal-weight non insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. Arch Gynecol Obstet 2015;291:955–7
   PubMed Web of Science ®Google Scholar
• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–9
   PubMed Web of Science ®Google Scholar
• Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685–97
   PubMed Web of Science ®Google Scholar
• Vitagliano A, Noventa M, Gizzo S. Is it time to consider patients suffering from endometriosis-related infertility as “novel candidates” for targeted peri-conceptional d-chiro inositol supplementation? Hypothesis, rationale, and some considerations. J Assist Reprod Genet 2015;32:407–8
   PubMed Web of Science ®Google Scholar
• Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol 2014;30:205–8
   PubMed Web of Science ®Google Scholar
• Laganà AS, Pizzo A. Authors’ reply to: “Empiric” inositol supplementation in normal-weight non-insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. Arch Gynecol Obstet 2015;291:959–60
   PubMed Web of Science ®Google Scholar
• Stovall DW, Bailey AP, Pastore LM. Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health (Larchmt) 2011;20:37–43
   PubMed Web of Science ®Google Scholar
• Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2000;52:81–6
   PubMed Web of Science ®Google Scholar
• Svendsen PF, Madsbad S, Nilas L. The insulin-resistant phenotype of polycystic ovary syndrome. Fertil Steril 2010;94:1052–8
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314–20
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon J-P, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8:417–23
   PubMedGoogle Scholar
• Gerli S, Papaleo E, Ferrari A, Di Renzo G. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11:347–54
   PubMed Web of Science ®Google Scholar
• Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009;13:105–10
   PubMed Web of Science ®Google Scholar
• Nordio M, Proietti E. The combined therapy with myo-inositol and D-Chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012;16:575–81
   PubMed Web of Science ®Google Scholar
• Minozzi M, Nordio M, Pajalich R. The combined therapy myo-inositol plus d-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci 2013;17:537–40
   PubMed Web of Science ®Google Scholar
• Laganà AS, Barbaro L, Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-chiro-inositol. Arch Gynecol Obstet 2015;291:1181–6
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Santagni S, Rattighieri E, et al. Modulatory role of d-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol 2014;30:438–43
   PubMed Web of Science ®Google Scholar
• Sacchinelli A, Venturella R, Lico D, et al. The efficacy of inositol and n-acetyl cysteine administration (ovaric HP) in improving the ovarian function in infertile women with PCOS with or without insulin resistance. Obstet Gynecol Int 2014;2014:141020
   PubMedGoogle Scholar
• Laganà AS, Pizzo A. Know your enemy: the rationale of using inositol in the treatment of polycystic ovary syndrome. Endocrinol Metab Syndr 2013;02:2–3
   Google Scholar
• Bevilacqua A, Carlomagno G, Gerli S, et al. Results from the international consensus conference on myo-inositol and d-chiro-inositol in obstetrics and gynecology–assisted reproduction technology. Gynecol Endocrinol 2015;31:441–6
   PubMed Web of Science ®Google Scholar
• Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet 2013;288:1405–11
   PubMed Web of Science ®Google Scholar
• Giordano D, Corrado F, Santamaria A, et al. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause 2011;18:102–4
   PubMed Web of Science ®Google Scholar
• Santamaria A, Giordano D, Corrado F, et al. One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric 2012;15:490–5
   PubMed Web of Science ®Google Scholar
• Capasso I, Esposito E, Maurea N, et al. Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trials 2013;14:273. doi: 10.1186/1745-6215-14-273
   PubMed Web of Science ®Google Scholar
• Malvasi A, Casciaro F, Minervini MM, et al. D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci 2014;18:270–4
   PubMed Web of Science ®Google Scholar
• Evans JL, Goldfine ID. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther 2000;2:401–13
   PubMedGoogle Scholar
• Ansar H, Mazloom Z, Kazemi F, Hejazi N. Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. Saudi Med J 2011;32:584–8
   PubMed Web of Science ®Google Scholar
• Zacchè MM, Caputo L, Filippis S, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:508–13
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Despini G, Santagni S, et al. Effects of a combination of alpha lipoic acid and myo-inositol on insulin dynamics in overweight/obese patients with PCOS. Endocrinol Metab Synd 2014;3:140. doi: 10.4172/2161-1017.1000140
   Google Scholar
• Cianci A, Panella M, Fichera M, et al. d-chiro-inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. Gynecol Endocrinol 2015;31:483–6
   PubMed Web of Science ®Google Scholar
• Le Donne M, Alibrandi A, Giarrusso R, et al. Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition. Minerva Ginecol 2012;64:23–9
   PubMedGoogle Scholar
• Raffone E, Rizzo P, Benedetto V. Insulin sensitizer agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol 2010;26:275–80
   PubMed Web of Science ®Google Scholar
• Cappelli V, Di Sabatino A, Musacchio MC, De Leo V. Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS. Minerva Ginecol 2013;65:425–33
   PubMedGoogle Scholar
• Oner G, Muderri II. Clinical, endocrine, and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2010;159:127–31
   Web of Science ®Google Scholar
• Minozzi M, Costantino D, Guaraldi C, Unfer V. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol 2011;27:920–4
   PubMed Web of Science ®Google Scholar
• Kamenov Z, Kolarov G, Gateva A, et al. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol 2015;31:131–5
   PubMed Web of Science ®Google Scholar